Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.

Complete Results!! !

But the company actually has never seen before wonderful results.

If results hold up, the stock will achieve massive gains.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

Alzheimer's is the most valuable and most difficult indication and most desired lately.. and only Anavex really has some great results with a great safety record. .

The sava results trounce you guys 🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

Sava has potential and the phase 3 results will show the truth.

Sava has good results. .

But the company actually has never seen before wonderful results.

And, make no mistake, the result are impressive.

It is the best results that have been seen in AD.

Overall, results impressive.

This could be huge in eliminating artificial FUD against the top-line results.

$SAVA Market is moving higher as SAVA is expecting data results.

Anavex is late like the sun comes up and still produces great results.

MOST IMPORTANTLY, THE RESULTS MUST HAVE BEEN GOOD AND PROMISING at each snapshot that leads Remi to use the word "Thrilled" in Dec 6 PR.

If so, then they must know that the results are going to be quite spectacular and market moving.

$HEPA from Twitter Madrigal Conference ▶️ $MDGL Per Management For potential Ex-USA partnership-Significant amount of interest and that interest has heightened significantly especially after Ph3 results per CEO!

Remarkable results i would say….

Yes very very interesting results.

The 28 day data also documented Rencofilstat’s amazingly fast & potent efficacy at reduction of fibrosis that in just 4 short weeks exceeded that of Madrigal’s 12 month hospitalization IV dosage results for their drug used in NASH.

I didnt sell a share and with stellar results for this soon to be released study it should gain traction well over 3 imo.

Brilliant move or some stellar early results.

• Treatment with RCF for 28 days results in a reduction in ceramides, free fatty acids, and triglycerides suggestive of a therapeutic benefit.

We knows recession is coming next year 4) XBI has bottomed and should begin its upward move next year 5) Phase 2b trial results and updates on HCC trial 6) Probable approvals of NASH drugs and increased bullish sentiment in the sector

button for good trial results in the NASH space.